Disease Progression in Patients with Multiple Myeloma is Associated with a Concurrent Alteration in the Expression of Both Oncogenes and Tumour Suppressor Genes and can be Monitored by the Oncoprotein Phenotype

References

• Vogelstein B., Kinger K. W. The multistep nature of cancer. Trends Genet. 1993; 9: 138–141
   PubMed Web of Science ®Google Scholar
• Vogelstein B., Fearon E. R., Hamilton S. R., Kern S. E., Preisinger A. C., Leppert M., Nakamura Y., White R., Smits A. M., Bos J. L. Genetic alterations during colorectal‐tumor development. New Engl. J. Med. 1988; 319: 525–532
   PubMed Web of Science ®Google Scholar
• Leppert M., Burt R., Hughes J. P., Samowitz W., Nakamura Y., Woodward S., Gardner E., Lalouel J. ‐M., White R. Genetic analysis of an inherited predisposition to colon cancer in a family with a variable number of ade‐nomatous polyps. New Engl. J. Med. 1990; 322: 904–908
   PubMed Web of Science ®Google Scholar
• Baker S. J., Fearon R., Nigro M., Hamilton S. R., Presinger A. C., Jessup J., van Tuinen P., Ledbetter D. H., Barker D. F., Nakamura Y., White R. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 224: 217–221
   Web of Science ®Google Scholar
• Bongiorno P. F., Whyte R. I., Lesser E. J., Moore J. H., Orringer M. B., Beer D. G. Alterations of K‐ras, p53, and erbB‐2/neu in human lung adenocarcinomas. J. Thome. Cardiovasc. Surg. 1994; 107: 590–595
   PubMed Web of Science ®Google Scholar
• Hollstein M., Sidransky D., Vogelstein B., Harris C. P53 mutations in human cancers. Science 1991; 253: 49–53
   PubMed Web of Science ®Google Scholar
• Iggo R., Gatter K., Bartek J., Lane D., Harris A. L. Increased expression of mutant forms of p53 onco‐gene in primary lung cancer. Lancet 1990; 335: 675–679
   PubMed Web of Science ®Google Scholar
• Marks J. R., Davidoff A. M., Kerns B. J., Humphrey P. A., Pence J. C., Dodge R. K., Clarke‐Pearson D. I., Ingehart J. D., Bast R. C., Berchuck A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Research 1991; 51: 2979–2984
   PubMed Web of Science ®Google Scholar
• Kaltoff H., Schmiegel W., Roeder C., Kasche D., Schmidt A., Lauer G., Thiele H. G., Honold G., Pantel K., Ritmuller G., Scherer E., Maurer J., Maacke H., Deppert W. P53 and K‐ras alterations in pancreatic epithelial cell lesions. Oncogene 1993; 8: 289–298
   PubMed Web of Science ®Google Scholar
• Volkenandt M., Schlegel U., Nanus D. M., Albino A. P. Mutational analysis of the human p53 gene in malignant melanoma. Pigment Cell. Res. 1991; 4: 35–40
   PubMedGoogle Scholar
• Kocialkowski S., Pezzela F., Morrison H., Jones M., Laha S., Harris A., Mason D. Y., Gatter K. C. Mutations in the p53 gene are not limited to classic “hot spots” and are not predictive of p53 protein expression in high‐grade non‐Hodgkin's lymphoma. Br. J. Haematol. 1995; 89: 55–60
   PubMed Web of Science ®Google Scholar
• Nobuyoshi M., Kawano M., Tanaka H., Ishikawana H., Tanabe O., Iwato K., Asaoku H., Sakai A., Kauramoto A. Increased expression of c‐myc gene may be related to the aggressive transformation of human myeloma cells. Br. J. Haematol. 1991; 77: 523–528
   PubMed Web of Science ®Google Scholar
• Paquette R. L., Berensen J., Lichtenstein A., McCormick F., Koefler H. P. Oncogenes in multiple myeloma: point mutations of N‐ras. Cancer Res. 1990; 5: 1659–1663
   Google Scholar
• Palumbo A. P., Boccadoro M., Battaglio S., Corradini P., Tsichlis P. N., Huebner K., Pileri A. Human homologous of Moloney leukaemia virus integration‐4 locus (MLVI‐4) located 20 kilobases 3′ of the c‐myc gene is rearranged in multiple myeloma. Cancer. Res. 1990; 50: 6478–6482
   PubMed Web of Science ®Google Scholar
• Selvanayagam P., Blick M., Narni F., van Tuinen P., Ledbetter D. H. Alteration and abnormal expression of the c‐myc oncogene in human multiple myeloma. Blood 1988; 71: 30–35
   PubMed Web of Science ®Google Scholar
• Brown R. D., Pope B., Luo X. ‐F., Gibson J., Joshua D. E. The oncoprotein phenotype of plasma cells from patients with multiple myeloma. Leak. Lymph. 1994; 16: 147–156
   PubMed Web of Science ®Google Scholar
• Dao D. D., Sawyer J. R., Epstein J., Hoover R. G., Barlogie B., Tricot G. Deletion of the retinoblastoma gene in multiple myeloma. Leukaemia 1994; 8: 1280–1284
   PubMed Web of Science ®Google Scholar
• Ahuja H. G., Foti A., Bar‐Eli M., Cline M. J. The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood 1990; 75: 1684–1690
   PubMed Web of Science ®Google Scholar
• Tanaka K., Takechi M., Asaoku H., Dohy H., Kamada N. A high frequency of N‐RAS mutations in multiple myeloma. Int. J. Haematol. 1992; 56: 119–127
   PubMed Web of Science ®Google Scholar
• Corradini P., Ladetto M., Voena C., Inghirami G., Knowles D. M. Mutational activation of N‐ and K‐ras oncogenes in plasma cell dyscrasias. Blood 1993; 81: 2708–2713
   PubMed Web of Science ®Google Scholar
• Neri A., Murphy J. P., Cro D., Ferroro D., Tarella C., Baldini L., Dalla‐Favera R. Ras oncogene mutations in multiple myeloma. J. Exp. Med. 1989; 170: 1715–1725
   PubMed Web of Science ®Google Scholar
• Portier M., Moles J. P., Mazares G. R., Jeanteu P., Bataille R., Klein B., Thillet C. p53 and RAS gene mutations in multiple myeloma. Oncogene 1992; 7: 2539–2543
   PubMed Web of Science ®Google Scholar
• Corradini P., Ingirami G., Astolfi M., Ladetto M., Voena C., Ballerini P., Gu W., Nilsson K., Knowles D. M., Boccadoro M., Pileri A., Dalla‐Favero R. Inactivation of tumour suppressor genes, p53 and Rbl in plasma cell dyscrasias. Leukaemia 1994; 8: 758–767
   PubMed Web of Science ®Google Scholar
• Predholmme C., Falcon T., Zandecki M., Vanrumbeke M., Lai J. L., Nataf E., Loucheux‐Lefebvre M. H., Kerckaert J. P., Fenaux P. Rare occurrence of p53 mutations in multiple myeloma. Br. J. Haematol. 1992; 81: 440–443
   PubMed Web of Science ®Google Scholar
• Neri A., Baldini L., Treeca D., Cro L., Polli E., Maiolo A. p53 gene mutations in multiple myeloma are associated with advanced forms of malignancy. Blood 1993; 81: 128–135
   PubMed Web of Science ®Google Scholar
• Joshua D. E., Snowdon L., Gibson J., Hand H., Brown R. D., Warburton P., Kulakarni A., Vincent P., Young G., Gatenby P., Basten A., Kronenberg H. Multiple myeloma: Plateau phase revisited. Haematol. Rev. 1991; 5: 59–66
   Google Scholar
• Brown R. D., Luo X. ‐F., Gibson J., Morley A., Sykes P., Brisco M., Joshua D. E. Idiotypic oligonucleotide probes to detect myeloma cells by mRNA in situ hybridization. Br. J. Haematol. 1995; 90: 113–118
   PubMed Web of Science ®Google Scholar
• Brown R. D., Joshua D. E., Nelson M., Gibson J., Dunn J., MacLennan I. C. M. Serum thymidine kinase as a prognostic indicator for patients with multiple myeloma: Results from the MRC V trial. Br. J. Haematol. 1993; 84: 238–241
   PubMed Web of Science ®Google Scholar
• Griepp P. R., Witzig T., Gonchoroff N. Immunofluorescent plasma cell labeling indices (LI) using a monoclonal antibody (BU‐1). Am. J. Hematol. 1985; 20: 289–292
   PubMed Web of Science ®Google Scholar
• IFCC and ICSH. Approved recommendation on the theory of reference values. J. Clin. Chem. Clin. Biochem. 1987; 25: 645–656
   Google Scholar
• Bergsagel P. L., Chesi M., Brents L. A., Kuehi W. M. Translocations into IgH switch regions: the genetic hallmark of multiple myeloma. Blood 1995; 86(Suppl 1)59a
   Google Scholar
• Bergsagel P. L., Chesi M., Brents L. A., Kuehi W. M. Dysregulation of c‐myc in multiple myeloma: selective expression of one allele. Blood 1995; 86(Suppl 1)59a
   Google Scholar
• Imamura J., Miyoshi I., Koeffler H. P. p53 in hematologic malignancies. Blood 1994; 84: 2412–2421
   PubMed Web of Science ®Google Scholar